Press releases

6 March, 2018

NeuroVive presents at the Stockholm Corporate Finance Life Science Seminar

Lund, Sweden, 6 March 2018, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) participates in the Stockholm Corporate Finance Life Science Seminar at Operaterassen on 7 March 2018 at 1 ...

15 February, 2018

Regulatory

Notice of Extraordinary General Meeting of NeuroVive Pharmaceutical AB (publ)

The shareholders of NeuroVive Pharmaceutical AB (publ), 556595-6538, are hereby convened to the Extraordinary General Meeting, held at 2 pm on Thursday 22 March 2018 at Medicon Village, Scheelevägen 2 ...

29 January, 2018

Regulatory

NeuroVive reports breakthrough in mitochondrial myopathy project

Lund, Sweden, 29 January 2018, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced a breakthrough in the company's project NVP025 for developing treatment of mitochondria ...

3 January, 2018

NeuroVive to Present at the 10th Annual Biotech Showcase Conference

Lund, Sweden, 3 January 2018 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), today announced that the company is scheduled to present the 10th Annual Biotech Showcase Conference, ...

13 December, 2017

Regulatory

NeuroVive’s KL1333 program granted orphan drug designation by the European Commission

Lund, Sweden, 13 December 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), announced today that the European Commission has granted orphan drug designation (ODD) for the compa ...

11 December, 2017

Regulatory

NeuroVive reports promising progress in its clinical project for genetic mitochondrial diseases, KL1333

Lund, Sweden, 11 December 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) and Yungjin Pharm today announced that the phase I clinical study in Korea within the companies' join ...

30 November, 2017

Regulatory

NeuroVive’s genetic mitochondrial disease program NVP015 reaches significant milestone

Lund, Sweden, 30 November 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that molecules in its NVP015 program have demons ...

15 November, 2017

NeuroVive presents TBI clinical study results at Nordic Neurotrauma Conference

Lund, Sweden, 15 November 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company will present data from its clinical phase IIa study on traumatic bra ...

8 November, 2017

Regulatory

NeuroVive’s Clinical Development Project KL1333 Receives Positive Opinion on European Orphan Drug Designation

Lund, Sweden, 8 November 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that the Committee for Orphan Medicinal Products ...

7 November, 2017

Regulatory

NeuroVive Board Chair Resigns, New Chair Elected

Lund, Sweden, 7 November 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announces that Gregory Batcheller resigned as Chair of the NeuroVive Pharmaceutical AB Board effective ...

31 October, 2017

Regulatory

NeuroVive signs collaboration agreement with University of Florida for TBI biomarker development

Lund, Sweden, 31 October 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company has signed a collaboration agreement with Kevin K.W. Wang, Ph.D., of ...

18 October, 2017

NeuroVive and Lund University Collaboration Receives Grant for Liver Cancer Research

Lund, Sweden, 18 October 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that NeuroVive and Ramin Massoumi at Lund Univers ...